Roche RHHBY announced that the late-stage study evaluating the combination therapy of tiragolumab plus Tecentriq (atezolizumab) and chemotherapy for the initial treatment of locally advanced unresectable or metastatic non-squamous non-small cell lung cancer patients failed to achieve its primary goals. Initial or first-line treatment refers to those patients who have previously not been treated for this indication. The phase II/III SKYSCRAPER-06 study evaluated Roche’s combination therapy compared with Merck’s MRK Keytruda (pembrolizumab) and chemotherapy in 542 patients with the lung cancer indication. The study's primary endpoints comprised progression-free survival (PFS) and overall survival (OS). Roche’s tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. The candidate’s unique mechanism of action suppresses the immune response to cancer and acts as an immune amplifier when combined with othercancer immunotherapies, such as Tecentriq. The study results showed that the combination of tiragolumab plus Tecentriq and chemotherapy was less effective in PFS and OS compared with the control group (Keytruda + chemotherapy). At the time of primary analysis, the PFS had a hazard ratio (HR) of 1.27, while the OS at its first interim analysis had an HR of 1.33, which was immature. Both data indicate reduced efficacy compared to treatment with Merck’s Keytruda and chemotherapy in the treated patient population, which includes the phase II and phase III cohorts. As a result, Roche intends to halt the phase II/III SKYSCRAPER-06 study and patients and investigators will be unblinded. The findings will be shared with health authorities and presented at a future medical meeting. The safety profile of the combination therapy of tiragolumab plus Tecentriq and chemotherapy was consistent with previous findings, with no new or unexpected issues. Roche further clarified that ongoing phase III studies of its combination therapy are exploring treatment settings and indications different than those in the SKYSCRAPER-06 study. Year to date, shares of RHHBY have lost 5.9% against the industry’s 21.1% growth. Zacks Investment Research Image Source: Zacks Investment Research Roche’s blockbuster immuno-oncology drug, Tecentriq, is currently approved in the United States, EU and several other countries to treat some of the most aggressive and difficult-to-treat forms of cancer, including advanced lung cancer, urothelial cancer and breast cancer. The drug also makes a significant contribution to the company’s top line. In the first quarter of 2024, Tecentriq recorded sales worth CHF 865 million, which represents year-over-year growth of 1%. Roche’s extensive development program for Tecentriq includes multiple ongoing and planned phase III studies across lung, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers. Merck’s Keytruda is currently marketed as the standard of care in the frontline treatment of metastatic non-small cell lung cancer patients. Keytruda, an anti-PD-1 therapy, is MRK’s blockbuster oncology drug. It is approved for several types of cancer, accounting alone for 47% of the company’s pharmaceutical sales in 2023. Keytruda is continuously growing and expanding into new indications and markets globally, bolstering Merck’s position in the oncology market. Merck’s Keytruda is presently approved to treat eight indications in earlier-stage cancers in the United States. Zacks Rank and Stocks to Consider Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the drug/biotech industryworth mentioning are ALX Oncology Holdings ALXO and Compugen CGEN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. In the past 30 days, the Zacks Consensus Estimate for ALX Oncology’s 2024 loss per share has remained constant at $2.89. During the same period, the consensus estimate for 2025 loss per share has remained constant at $2.73. Year to date, shares of ALXO have plunged 62.4%. ALX Oncology beat estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 8.83%. In the past 30 days, the Zacks Consensus Estimate for Compugen’s 2024 earnings per share has remained constant at 5 cents. The consensus estimate for 2025 loss per share is currently pegged at 11 cents. Year to date, shares of CGEN have lost 15.7%. CGEN’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 5.79%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY):Free Stock Analysis Report Merck & Co., Inc. (MRK):Free Stock Analysis Report Compugen Ltd. (CGEN):Free Stock Analysis Report ALX Oncology Holdings Inc. (ALXO):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...